Tumor-infiltrating lymphocytes predict efficacy of immunotherapy in advanced non-small cell lung cancer: a single-center retrospective cohort study

Figures & data

Table 1. Patient demographics and baseline characteristics.

Variables	Training cohort Total (N = 62)	Validation cohort Total (N = 27)	p value
Age
>60	35 (56.5)	12 (44.4)	0.297
≤60	27 (43.5)	15 (55.6)
Gender
Male	38 (61.3)	14 (51.9)	0.406
Female	24 (38.7)	13 (48.1)
Smoker/ex-smoker	26 (41.9)	9 (33.3)	0.445
ECOG PS score (0-1)	38 (61.3)	18 (66.7)	0.629
Stage
III	19 (30.6)	6 (22.2)	0.416
IV	43 (69.4)	21 (77.8)
Histopathology
Adenocarcinoma	40 (64.5)	17 (73.0)	0.888
Squamous carcinoma	22 (35.5)	10 (37.0)
Timing of immunotherapy
First line	13 (21.0)	8 (29.6)
Second line	33 (53.2)	15 (55.6)	0.443
≥Third line	16 (25.8)	4 (14.8)
Previous treatment
Chemotherapy	49 (79.0)	19 (70.4)	0.827
Anti-angiogenesis therapy	34 (54.8)	12 (44.4)
Types of ICIs
Nivolumab	13 (21.0)	6 (22.2)
Pembrolizumab	9 (14.5)	10 (37.1)
Sintilimab	19 (30.6)	7 (25.9)	0.174
Camrelizumab	5 (8.1)	0 (0.0)
Tislelizumab	8 (12.9)	3 (11.1)
Toripalimab	8 (12.9)	1 (3.7)

Data are shown as n (%). ECOG PS: eastern co-operative oncology group performance status; ICIs: immune checkpoint inhibitors.

Figure 1. Representative pictures of TILs infiltration density by immunohistochemical staining (×200). CD8⁺ TILs with high (a) and low (b) infiltration density. CD4⁺ TILs with high (c) and low (d) infiltration density. IFN-γ⁺ Th1 with high (e) and low (f) infiltration density. IL-4⁺ Th2 with high (g) and low (h) infiltration density. Foxp3⁺ Treg with high (i) and low (j) infiltration density.

Figure 2. Forest plot for Cox regression analysis of PFS in the training cohort.

Figure 3. Forest plot for Cox regression analysis of OS in the training cohort.

Figure 4. Nomogram prediction model construction and validation. Nomogram prediction model (a) constructed based on multivariate Cox analysis. Time-dependent AUC in the training cohort (b) and validation cohort (c). nomogram calibration curves in the training cohort (d) and validation cohort (e).

Data availability statement

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.